Physician profile
David E Anderson
NPI 1063413789
$5,599.70
in general payments reported to CMS, 2019-2025
32 companies · $189 in 2025
The $189 reported for 2025 was less than what a typical Sleep Medicine (Internal Medicine) provider received nationally (typical 2025 total: $447).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,009 · 2020: $483 · 2021: $558 · 2022: $391 · 2023: $1,739 · 2024: $1,231 · 2025: $189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,547 · Education: $612.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,546.53 |
| Education | $611.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $913.31 | 2019-2024 | Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals LP | $881.96 | 2019-2024 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $594.40 | 2019-2024 | Trelegy Ellipta, Arexvy, Nucala |
| Mallinckrodt Hospital Products INC. | $523.89 | 2020-2024 | Acthar |
| Harmony Biosciences LLC | $355.56 | 2021-2025 | Wakix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $351.64 | 2019-2025 | Ofev, Jascayd |
| Merck Sharp & Dohme LLC | $309.67 | 2021-2024 | Verquvo, Winrevair, Belsomra |
| Bayer Healthcare Pharmaceuticals INC. | $226.38 | 2021-2024 | |
| Mylan Specialty L.P. | $185.19 | 2019-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $171.82 | 2019-2023 | |
| Grifols USA, LLC | $132.45 | 2019-2023 | Xembify |
| Jazz Pharmaceuticals INC. | $116.85 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $113.22 | 2019-2020 | |
| Genentech USA, INC. | $88.97 | 2019-2024 | Xolair |
| Amgen INC. | $82.86 | 2019-2023 | Tezspire |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $75.92 | 2019-2024 | Orenitram, Remodulin |
| Resmed Corp | $57.80 | 2019 | |
| Sunovion Pharmaceuticals INC. | $50.08 | 2019 | |
| Advanced Respiratory, INC | $44.19 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $42.99 | 2023-2024 | Dupixent |
| Philips North America LLC | $42.75 | 2019 | |
| Mallinckrodt Enterprises LLC | $42.61 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $34.48 | 2021-2023 | Eliquis |
| Inspire Medical Systems, INC. | $27.56 | 2024 | Inspire |
| Insmed, INC. | $25.46 | 2021-2023 | Arikayce |
| Veran Medical Technologies, INC. | $20.15 | 2020 | |
| Idorsia Pharmaceuticals US INC | $18.38 | 2023 | Quviviq |
| Pfizer INC. | $17.96 | 2023 | |
| Medtronic, INC. | $15.32 | 2021 | |
| Ethicon INC. | $14.00 | 2021 | |
| Covidien LP | $12.38 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $9.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.